HBP Stock Overview
Operates as an immune-oncology company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Helix BioPharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.70 |
| 52 Week High | CA$1.35 |
| 52 Week Low | CA$0.50 |
| Beta | -0.84 |
| 11 Month Change | -40.17% |
| 3 Month Change | -41.67% |
| 1 Year Change | -39.13% |
| 33 Year Change | -72.55% |
| 5 Year Change | -87.27% |
| Change since IPO | -84.44% |
Recent News & Updates
Shareholder Returns
| HBP | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 2.9% | -8.5% | 0.7% |
| 1Y | -39.1% | 1.5% | 21.7% |
Return vs Industry: HBP underperformed the Canadian Biotechs industry which returned 1.5% over the past year.
Return vs Market: HBP underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| HBP volatility | |
|---|---|
| HBP Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: HBP's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: HBP's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Jacek Antas | www.helixbiopharma.com |
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor.
Helix BioPharma Corp. Fundamentals Summary
| HBP fundamental statistics | |
|---|---|
| Market cap | CA$34.32m |
| Earnings (TTM) | -CA$9.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs HBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$9.26m |
| Earnings | -CA$9.26m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HBP perform over the long term?
See historical performance and comparison